Scienture Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $18.5M
- Price
- $0.4558
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.39%
- Volume
- 131.1K
About
As a health services IT enterprise, TRxADE HEALTH, Inc. manages an online platform designed to facilitate transactions between licensed pharmaceutical wholesalers and healthcare providers. This digital marketplace enables wholesalers to distribute a broad spectrum of products and services, encompassing branded and generic drugs as well as other non-pharmaceutical items. Customers for these offerings span government organizations, hospitals, medical clinics, and independent pharmacies. The firm's corporate base is situated in Tampa, Florida.
Quick stats
Shares outstanding40.6M
Computed float36.8M
Float / shares90.5%
Key info
SectorHealthcare
IndustryMedical - Healthcare Information Services
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001382574
Websitehttps://scienture.com
AI Summary
AI-generated1/12
majorbullishearnings
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
Scienture reported Q2 2026 revenue of $343,639, a 510% increase from the prior quarter, with gross margins expanding to 97.7%.
Operating expenses decreased 41% year-over-year to approximately $3.0 million, narrowing the net loss by 58% to $2.8 million.
The company commenced the commercial launch of REZENOPY and ended the quarter with $11.2 million in cash and restricted cash.
Red flags
- Q2 revenue remains nominal at $343,639 despite high percentage growth
- Accumulated deficit stands at $86.8 million
- Net loss of $2.8 million persists despite cost reductions